🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "major milestone" in the fight against superbug strains of the pathogen, according to health experts.

A Worldwide Public Health Issue

Cases of gonorrhoea are increasing worldwide, with figures suggesting more than 82 million infections annually. Particularly high rates are reported in the African continent and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the reality of rising global incidence, escalating drug resistance and the extremely scarce treatment choices presently on offer.”

Health officials are deeply concerned about the increase in treatment-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Gain Clearance

One new antibiotic, alternatively called a brand name, was approved by the US FDA in December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Experts hope that targeted use of this new drug will help hinder the development of resistance.

Another new antibiotic, created by the pharmaceutical company GSK, also received approval in concurrent days. This drug, which is employed against urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization signifies a huge turning point in the treatment of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Results and Global Access

As per results published in a prominent scientific publication, zoliflodacin successfully treated more than 90% of genital gonorrhoea infections. This places it at an similar efficacy with the current standard treatment, which combines two antibiotics. The study enrolled hundreds of patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to license and sell the drug in a wide range of low-income and middle-income countries.

Doctors on the front lines have voiced positive views. Having a easy-to-administer therapy like this is described as a "game-changer" for gonorrhoea control. This is considered crucial to reduce the burden of the disease for people and to prevent the spread of extremely resistant gonorrhoea globally.